Walleye Trading’s Kalaris Therapeutics KLRS Stock Holding History

Walleye Trading’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-629	Closed	-$187K	–	5997
2021 Q4	$187K	Buy	+629	New	+$292K	﹤0.01%	3932

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Walleye Trading's KLRS Position: Q1 2022 in Review

Walleye Trading sold out of Kalaris Therapeutics (KLRS) in Q1 2022, closing a stake of 629 shares — an estimated $187K sold.

Walleye Trading first reported a position in KLRS in Q4 2021 and held it in 1 quarter. The position peaked at $187K in Q4 2021. 84 funds tracked by Wall St. Rank hold KLRS as of Q1 2022.

Walleye Trading reported no remaining Kalaris Therapeutics position as of Q1 2022 after selling out during the quarter.
Walleye Trading sold 629 Kalaris Therapeutics shares in Q1 2022, an estimated $187K.
Walleye Trading first reported a position in Kalaris Therapeutics in Q4 2021 and held it in 1 quarter.
Walleye Trading's Kalaris Therapeutics position peaked at $187K in Q4 2021.
84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2022.

Based on Walleye Trading's 13F filing for Q1 2022, filed 16 May 2022.